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Mitogen-activated protein kinase (MAPK)
Receptor tyrosine kinaseSyndecan-1 is a proteoglycan that acts as co-receptor through its heparan sulfate (HS) chains andplays important
roles in cancer. HS chains are highly variable in length and sulfation pattern. This variability is enhanced by the
SULF1/2 enzymes, which remove 6-O-sulfates from HS. We used malignant mesothelioma, an aggressive
tumor with poor prognosis, as a model and demonstrated that syndecan-1 over-expression down-regulates
SULF1 and alters the HS biosynthetic machinery. Biochemical characterization revealed a 2.7-fold reduction in
HS content upon syndecan-1 over-expression, but an overall increase in sulfation. Consistent with low SULF1
levels, trisulfated disaccharides increased 2.5-fold. ERK1/2 activity was enhanced 6-fold. Counteracting ERK acti-
vation, Akt, WNK1, and c-Jun were inhibited. The net effect of these changes manifested in G1 cell cycle arrest.
Studies of pleural effusions showed that SULF1 levels are lower in pleural malignancies compared to benign con-
ditions and inversely correlate with the amounts of syndecan-1, suggesting important roles for syndecan-1 and
SULF1 in malignant mesothelioma.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the license CC BY-NC-ND
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Syndecans are transmembrane heparan sulfate proteoglycans
(HSPGs) that contain a core protein with a large N-terminal extracellu-
lar domain to which heparan sulfate (HS) chains covalently attach
[1–3]. HSPGs play crucial roles as co-receptors in various signaling path-
ways by cooperatingwith receptor tyrosine kinases (RTKs) and altering
signal transduction [2,4,5]. The HS chains of syndecans act as high afﬁn-
ity binding sites for various soluble growth factors, such as ﬁbroblast
growth factor (FGF), vascular endothelial growth factor (VEGF), and
heparin binding-epidermal growth factor (HB-EGF), and facilitate
their presentation to receptors [6–8]. These interactions between HS
and biological effectors modify the stability, availability, and/or activity
of HS binding partners by affecting their local concentrations and
controlling their diffusion [9,10]. HS chains consist of repeating disac-
charide units of N-acetyl-glucosamine (GlcNac) and uronic acid (glucu-
ronic acid, GlcA, or iduronic acid, IdoA) bound to serine residues on theidari-Hamedani).
. This is an open access article undercore proteins through a tetrasaccharide linkage. Synthesis of the HS chain
continues with chain elongation, followed by a series of enzymatic mod-
iﬁcations, including deacetylation, epimerization, and sulfation, which re-
sult in broad diversity in theHS structure and lead to a varying capacity to
bind molecules, such as growth factors, cytokines, chemokines, enzymes,
matrix proteins, and numerous cell surface receptors [11]. In addition,
several post-synthetic changes can occur at the cell surface and affect
HS structure and function: i) fragmentation of HS by heparanase into
oligosaccharides of different lengths, regulating the release of HS-bound
ligands [12]; ii) selective removal of the 6-O-sulfate groups from HS
chains by the two isoforms of extracellular endosulfatases, SULF1 and
SULF2; and iii) shedding of the core protein ectodomain with the HS
chains from the cell surface by sheddases. The shed syndecans may act
as competitive inhibitors formembraneHSPGs or alter growth factor gra-
dients in the neighborhood of the cell [13].
Syndecan-1 (SDC1) has dual roles in different cancer types by being
either an inhibitor or promoter of tumor progression [14]. It is involved
in cell proliferation, adhesion, migration, and angiogenesis, but its ex-
pression diverges in various tumor types [14–16]. Generally, SDC1 ex-
pression is higher in epithelial malignancies than in mesenchymalthe license CC BY-NC-ND(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Primer sequences used for qPCR.

























2055G. Heidari-Hamedani et al. / Cellular Signalling 27 (2015) 2054–2067tumors. Modiﬁcation of the 6-O-sulfate content of HS has also been as-
sociated with altered biological properties and tumor progression, with
6-O-sulfation being crucial in growth factor binding and activity such as
shown for FGF, where 6-O-sulfation is essential for the formation of the
FGF2/FGFR/HS signaling complex and its mitogenic activity [17–20].
Studies have implied that, similar to SDC1 levels, SULF1 levels are dys-
regulated in cancer. The action of SULF1may be also different in the con-
text of tumors; in some tumor types SULF1 expression is decreased,
whereas in others it is increased [10]. Because SDC1 acts by binding a
wide range of heparin-binding growth factors and their corresponding
receptors through its polysaccharide chains [21–24], HS chainmodiﬁca-
tions should be studied in different tumor types.
Malignant mesothelioma (MM) is one of the most aggressive mes-
enchymal tumors. It is difﬁcult to diagnose, and has poor prognosis
[25]. SDC1 expression is generally low in MM compared to epithelial
cancers, and its expression in these tumors correlates with epithelioid
differentiation and better prognosis [26]. Previously, we showed that
over-expression of SDC1 has profound effects on the main signal trans-
duction pathways in a mesothelioma cell line, regulating cell growth
and cell cycle progression. Enzymes important to the HS sulfation
pattern were also affected by SDC1 over-expression [27], leading to
the hypothesis that higher SDC1 levels may result in HS structural rear-
rangements, which in turn affect the growth factor bindingproperties of
the whole HSPG pool. These alterations may contribute to the effects of
SDC1 on cell proliferation and cell cycle distribution.
The aim of this study was to examine in detail the effect of SDC1 on
the HS chain composition of proteoglycans and the mechanisms
through which these changes subsequently affect signaling pathways
in mesothelioma cells. To verify the general applicability of our ﬁndings
at clinical level, we monitored the relationship between soluble SDC1
and SULF1 in pleural effusions from cancer patients.
2. Materials and methods
2.1. Cell line and cell culture conditions
Human malignant mesothelioma cells with epithelioid morphology
(STAV-AB) were used. This cell linewas chosen based on its low endog-
enous SDC1 expression [28]. Cells were grown in RPMI 1640 Glutamax
medium (Life Technologies Inc., Paisley, UK) supplemented with 10%
human AB serum. Incubation was performed in a humidiﬁed atmo-
sphere containing 5% (v/v) CO2 at 37 °C. SDC1 was stably over-
expressed by transfection with a plasmid vector carrying the human
full-length SDC1 gene as described previously [29]. Cells transfected
with the same plasmid vector carrying no constructs were used as
negative mock controls in all experiments. Stable overexpression was
obtained by Geneticin selection (G418; Roche Diagnostics GmbH,
Mannheim, Germany).
2.2. Microarray analysis
Microarray analysis of STAV-AB cells over-expressing SDC1 vs. cells
transfected with empty vector was performed using the GeneChip®
Human Gene 1.0 ST Array (Affymetrix Inc., Santa Clara, CA, USA) as de-
scribed previously [27]. A fold change of ≤1.5 or N1.5 and differential ex-
pression were considered with a q-value of ≤0.05.
2.3. Reverse-transcription polymerase chain reaction
Quantitative real-time reverse-transcription polymerase chain reac-
tion (qRT-PCR)was used to investigate the expression of different genes
involved in HS chain synthesis and different HSPGs. Total RNA was
isolated from sub-conﬂuent cells using the high pure RNA isolation kit
(Roche, Mannheim, Germany) according to the manufacturer's instruc-
tions. The yield and purity of the RNAwere estimated spectrophotomet-
rically by measuring the UV absorbance at 260 and 280 nm with aNanoDrop spectrophotometer (NanoDrop Technologies Inc.). cDNA was
synthesizedusing aﬁrst strand cDNAsynthesis kit (AmershamPharmacia
Biotech., Little Chalfont, Buckinghamshire, UK). Three independent RNA
isolates were reverse transcribed for the subsequent qPCR using the
Platinum® SybrGreen qPCR SuperMix-UDG kit (Invitrogen, Carlsbad,
CA, USA). The primer sets for target geneswere obtained fromCyberGene
AB (Sweden) (Table 1). Primers were designed using Primer3 software
(Steve Rozen, Helen J. Skaletsky, Primer3, http://www-genome.wi.mit.
edu/genome_software/other/primer3.html.,1998) and gene sequences
from GenBank (NCBI). All reactions were performed in a total volume of
10 μL in an iCycler machine (BioRAD) in triplicate. The relative quantity
of each target was normalized to GAPDH as a reference gene using the
ΔΔCt method.2.4. Preparation and disaccharide analysis of heparan sulfate chains
by reverse-phase ion-pair high-performance liquid chromatography
(RPIP-HPLC) analysis
Preparation and puriﬁcation of HS chains from cells over-expressing
SDC1 and control STAV-AB cells were performed as described previous-
ly [30,31]. Brieﬂy, cell culture mediumwas collected and cell layers ex-
tensively digested with trypsin (50 min at 37 °C). After centrifugation,
supernatants were applied to a DEAE-Sephacel column (2 mL) equili-
brated in 20 mM phosphate pH 6.5. The column was then extensively
washed with 20 mM phosphate pH 6.5 and 0.3 M NaCl. GAG chains
were step-eluted with 20 mM phosphate pH 6.5 and 1 M NaCl. Recov-
ered samples were desalted over a Pd-10 column, lyophilized, and
stored at−20 °C prior to analysis.
GAG sampleswere resuspended in 100mMsodiumacetate (pH 7.1)
and 0.5 mM calcium and HS were exhaustively digested to disaccha-
rides by incubation with heparinase I (10 mU, Grampian enzymes,
Orkney, UK) overnight at 30 °C, followed by a second incubation with
heparinase II and heparinase III (10 mU each, Grampian enzymes) for
24 h at 37 °C. Compositional analysis was then performed by RPIP-
HPLC as described previously [32]. Samples were applied to a Luna 5u
C18 reversed phase column (4.6 × 150 mm, Phenomenex) equilibrated
at 1.1mL/min in 1.2mM tetra-N-butylammoniumhydrogen sulfate and
8.5% acetonitrile, and then resolved using a NaCl gradient (0–8 mM in
10 min, 8–30 mM in 1 min, 30–56 mM in 11.5 min, 56–106 mM in
1.5 min, and 106mM for 6 min) calibrated with disaccharide standards
(Calbiochem). On-line post-column disaccharide derivatization was
achieved by the addition of 2-cyanoacetamide (0.25%) in NaOH (0.5%)
at a ﬂow rate of 0.35 mL/min, followed by ﬂuorescence detection (exci-
tation 346 nm, emission 410 nm). Due to a low amount of recoverable
material, HS puriﬁcation and digestion were performed by pooling ex-
tracts from three independent cultures.
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Preparation and enzymatic degradation of cells' over-expression
SDC1 and control STAV-AB cells were performed by detaching the
cells, and after removing the medium, digesting them for 6 min in
0.05% trypsin at 37 °C. The mixture was centrifuged at 2200 g and the
trypsin-resistant proteoglycans in the pellet further digested in a
20 mM acetate buffer (pH 7.0) containing 1 μmol calcium acetate and
0.3 units each of heparinase I (heparin lyase I, EC 4.2.2.7), heparinase
II (heparin lyase II, no EC number), and heparinase III (heparin lyase
III, EC 4.2.2.8) per milligram of polysaccharide (dry weight) at 37 °C
overnight [33]. Enzymatic degradation was terminated by boiling the
samples for 1 min. After 10 min of centrifugation at 13,000 g, superna-
tants were analyzed by HPCE. Analysis was performed on anHP3DCE in-
strument (Agilent Technologies, Waldbronn, Germany) with a diode
array detector. Separation and analysis were carried out on an uncoated
fused silica capillary tube (50 μm i.d., 64.5 cm total length, 56 cm effec-
tive length) at 25 °C. The operating buffer for HS standard disaccharides
and sample analysis was 15 mM sodium orthophosphate/phosphoric
acid buffer at pH 3.5 ﬁltered through a 0.2-μm membrane ﬁlter and
degassed in an ultrasonic bath. Electrophoresis was performed at
30 kV reversing polarity [34]. Before each run, the capillary tube was
washed with 0.1 M NaOH for 1 min, with water for injection for
2 min, and with the operating buffer for 5 min. After each analysis, the
capillary was post-conditioned with water for 2 min.
The operating buffer replenishment mode of the CE instrument was
used during electrophoresis. Samples were introduced hydrodynami-
cally using the pressure injection mode. Detection was performed at
232 nm [35]. Peak areas were recorded and evaluated using the HP
Kayak XA software system HP3D CE ChemStation. Identiﬁcation and
quantiﬁcation of theΔ-disaccharide content in sampleswere performed
using precisely known amounts of disaccharide standards dissolved in
heparanase digestion buffer as working solutions. Heparinases, all
from Flavobacterium heparinium, and the HS-derived Δ-disaccharide
standards were purchased from Sigma (St. Louis, MO, USA).
2.6. Fluorescence activated cell sorting (FACS) analysis
2.6.1. Detection of heparan sulfate-modulating enzymes, ERK1/2, Akt, and
ETS-1 expression and activity
For cell surface staining, cellswere detached using an enzyme-free cell
dissociation buffer (Gibco, 13151-014) for 15min, and thenwere scraped
if necessary. Cells were collected, counted, and ﬁxed in 2% buffered form-
aldehyde. Incubationwithprimary antibodies against total andphosphor-
ylated ERK1/2, Akt, and ETS-1 or corresponding isotype controls at the
same concentration (Table 2) was performed for 40 min at 4 °C. After
washing, cells were stained with Alexa 488-conjugated goat anti-rabbitTable 2
Antibodies and negative controls used.
Antibody Company Dilution
Anti-p44/42 MAPK (Erk1/2) rabbit monoclonal(137 F5) Cell Signaling 1/100
Anti-phospho-p44/42 MAPK (Erk1/2) (Erk1/2)
(Thr202/Tyr204) XP® rabbit monoclonal (D13.14.4E)
Cell Signaling 1/200




Anti-ETS1 mouse monoclonal (8A8) Abcam 1/200
Anti-ETS1(phospho T38) rabbitpolyclonal Abcam 1/200
Anti-sulfatase-1 rabbit polyclonal Abcam 1/50
Anti-HS6ST1 rabbit polyclonal Abcam 1/500
Anti-HS2ST1 mouse monoclonal(G-10) Santa Cruz
Biotech.
1/10
Mouse IgG1 isotype control Dako –
Rabbit IgG isotype control Cell Signaling –
F(ab′) fragment of Alexa488 goat α-mouse IgG (H + L) Invitrogen 1/800
Alexa488 goat α-rabbit IgG (H + L) Invitrogen 1/400or goat anti-mouse secondary antibody for 15 min at room temperature
(RT). Intracellular staining was performed by detaching the cells using a
0.05% trypsin-EDTA dissociation reagent (Gibco, 15400-054) for 3 min.
Cells were ﬁxed and permeabilized with 2% formaldehyde, followed by
90% methanol for 10 min, and the same staining protocol used as de-
scribed above.
Before growth factor stimulation, cells were starved overnight in a
serum-freemedium before staining andwere incubated for 6 h in ame-
dium supplemented with VEGF and PDGF-AB (5 ng/mL, Peprotech, NJ,
USA) or 5 min with FGF2 (10 ng/mL, PeproTech, NJ, USA).
2.6.2. Sulfatase-1 activity assays
The expression of different HS epitopes at the surface of cells over-
expressing SDC1 was detected by phage display-derived anti-HS
antibodies produced in a VSV-tag version to recognize epitopes with
different sulfation patterns (Table 3). Cells were detached using a cell
dissociation buffer (Gibco) or scraped, resuspended in FACS buffer,
and incubated 30 min at 4 °C with antibodies against different HS epi-
topes in 1/50 dilution. For the detection of bound antibodies, cells
were incubated in 100 μL of FACS buffer containing 1/10 mouse mono-
clonal anti-VSV tag glycoprotein, clone P5D4 (Sigma-Aldrich, V-5507)
at 4 °C for 30 min. After washing, cells were incubated in a FACS buffer
containing 1/200 Alexa488 goat anti-mouse IgG (H+ L) antibody (Mo-
lecular Probes, A-11001) for 15min at RT. For negative controls, the pri-
mary antibody was omitted.
Recombinant SULF1 was produced as described previously by
transfecting FreeStyle 293-F cells (Invitrogen) with a pcDNA3.1/Myc-
His(−) plasmid encoding SULF1 [36,37]. To study the activity of
SULF1, cells over-expressing SDC1 and control mock-transfected cells
were starved overnight. The culture medium was then replaced by
1 mL of medium supplemented with 2.5 μMMgCl2 and 20 μL of recom-
binant SULF1 and incubated for an additional 2.5 h. Cellswere harvested
and stained for HS epitopes as described above. For all experiments,
cells were analyzed in 250 μL PBS using a FACSCalibur cytometer
(Becton Dickinson) and CELLQuest software. For each analysis set, at
least three independent experiments were performed, with at least
6000 cells counted for each sample.
2.7. Immunocytochemistry
Cellswere grown to 70% conﬂuence in eight-well Lab-Tek II chamber
slides (Thermo Scientiﬁc, 154941) and were ﬁxed with 3% paraformal-
dehyde for 10 min. For intracellular staining, cells were subsequently
permeabilized with 0.1% Triton X-100 (Sigma, St Louis, MO, USA)
for10 min at RT. Non-speciﬁc binding was blocked with a 3% normal
goat serum for 30 min at RT, and cells were incubated (overnight at
4 °C) with primary antibodies or corresponding isotype control
(Table 2) in PBS/1% bovine serum albumin. Slides were rinsed and incu-
bated for 30 min at RT with Alexa 488 conjugated secondary antibody
diluted in 1% BSA. Slides were then counterstained with Hoechst
33342 dye (Life Technologies, H3570) andmounted usingDako ﬂuores-
cent mounting medium (S3023). Laser scanning microscopy was per-
formed using a Nikon Eclipse Ti confocal microscope and NIS Elements
AR imaging software. Images were processed using ImageJ 1.47
software.Table 3
VSV-tagged phage display-derived scFv anti-heparan sulfate antibodies [77].
Anti-HS antibody HS modiﬁcations
HS4C3 N-sulfation, 3-O-, 6-O-, 2-O-sulfation
HS4E4 N-sulfation, N-acetylation, C5-epimerization
AO4B08 N-sulfation,C5-epimerization 2-O-, 6-O-sulfation
RB4EA12 N-acetylation, N-sulfation, 6-O-sulfation
NS4F5 N-sulfation,C5-epimerization, 2-O-sulfation, 6-O-sulfation
EV3C3 N-sulfation, C5-epimerization, 2-O-sulfation
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Cells over-expressing SDC1 and corresponding control cells were
grown to 70% conﬂuence in eight-well Lab-Tek II chamber slides for
48 h, and then were washed and incubated in 200 μL of conditioned
medium from SNAP-tagged SULF1-expressing 293-F cells at 4 °C.
SNAP-tagged SULF1 was prepared similarly to recombinant SULF1
after insertion of the SNAP-coding sequence at the N-terminus of
the SULF1 sequence. After 1 hour incubation with SNAP-tagged
SULF1, cells were washed with culture medium without serum and
were incubated in 5 μM SNAP-surface 488 (Bio-Labs, S9124S) ac-
cording to the manufacturer's instructions at 4 °C. Cells were ﬁxed
in 3% paraformaldehyde for 10 min, counterstained with Hoechst
33342 dye (Life Technologies, H3570), and mounted in Dako mount-
ing medium. Cell-bound SULF1 was visualized and compared to cells
without SULF1 incubation. Laser scanning microscopy was per-
formed using a Nikon Eclipse Ti confocal microscope and NIS Ele-
ments AR imaging software. Images were processed using ImageJ
1.47 software.2.9. Proteome proﬁler arrays
To proﬁle the RTK phosphorylation status of cells over-expressing
SDC1, we used the human phospho-RTK aRRAY kit (R&D Systems,
Inc.). To investigate the activation status of downstream signaling path-
ways,we also analyzed the phosphorylation of 43 kinases using the pro-
teome proﬁler human phospho-kinase array kit (R&DSystems, Inc.). For
both kits, cells over-expressing SDC1 and corresponding controls were
stimulated for 6 hwith amixture of growth factors containing recombi-
nant human VEGF (5 ng/mL) (Peprotech, NJ, USA) and PDGF-AB
(5 ng/mL) (Peprotech, NJ, USA) in complete medium. The protein con-
centrations of cell lysates were measured using the bicinchoninic acid
(BCA) assay (Thermo Scientiﬁc, IL, USA, cat. no. 23225). Equal amounts
of total protein in cell lysates were mixed with a cocktail of biotinylated
detection antibodies and added to nitrocellulose membranes coated
with primary antibodies. Following streptavidin-HRP and chemilumi-
nescent detection, the amount of analyte at each spot was recorded
with a CCD camera (FluorChem™ SP, Alpha Innotech, USA) and optical
pixel densities were analyzed using the ImageJ open source image anal-
ysis program.Fig. 1. SDC1 alters the expression of HS synthesizing andmodifying enzymes. (a) RNA expressio
expression. Black bars representmicroarray results at a q value of ≤0.05; gray bars represent RT
iﬁcation following SDC1 over-expression,measured byﬂuorescence activated cell sorting (FACS
(SEM). Signiﬁcance was assessed by one sample t-test. Asterisk indicates signiﬁcance at p ≤ 0.02.10. Nuclear extraction
In order to prepare nuclear extracts containing activated transcrip-
tion factors, the active motif nuclear extraction kit (Rixensart,
Belgium, cat. no. 40010) was used according to the manufacturer's in-
structions. Brieﬂy, 2 × 106 cells were stimulated for 6 h with a mixture
of VEGF (5 ng/mL, Peprotech, NJ, USA) and PDGF-AB (5 ng/mL,
Peprotech, USA) in a complete medium. Cells were collected in ice-
cold PBS containing phosphatase inhibitors, and thenwere resuspended
in hypotonic buffer containing detergents. After removal of the cyto-
plasmic fractions, cell nuclei were lysed in the lysis buffer containing
protease inhibitors and 10 mM DTT. Nuclear proteins were solubilized
in this buffer and the protein concentrations were measured using the
BCA assay and using optical densities at 562 nm.
2.11. Transcription factor assay
The activity of transcription factors was detected using the
TRansAm™MAPK family kit (Active Motif, CA, USA). The kit is designed
speciﬁcally to study the MAPK-regulated transcription factors ATF-2, c-
Jun, c-Myc, MEF-2, and STAT-1a. Brieﬂy, this kit is an ELISA-based assay
in which the activated transcription factors from the nuclear extract
bind coated oligonucleotides. The amount of bound factor is then quan-
tiﬁed using antibodies speciﬁc for each factor in its active form. Optical
densities weremeasured at 450 nmand compared to 655 nmas the ref-
erence wavelength.
2.12. Soluble syndecan-1and sulfatase-1 enzyme-linked immunosorbent
assay (ELISA) of pleural effusions
Sixty-six pleural effusions comprising 17 adenocarcinomas (four
breast carcinomas, four ovarian carcinomas, four lung carcinomas, two
colorectal carcinomas, one renal carcinoma, one esophageal carcinoma
and one from unknown primary tumor), 37 malignant mesotheliomas,
and 12 benign effusions were used to measure soluble SDC1 and
SULF1 levels. Forty-two effusions were collected at the Department of
Pathology and Cytology, Karolinska University Hospital in Huddinge,
Sweden, between 2007 and 2013. Twenty-four MM effusions were col-
lected at the Chest Disease Department of Eskisehir Osmangazi Univer-
sity in Eskisehir, Turkey, between 2002 and 2004. The samples were
collected before any treatment was given. Inclusion criteria have beenn of different compounds involved in HS synthesis andmodiﬁcation following SDC1 over-
-PCR validation; (b) expression of different proteins involved in HS biosynthesis andmod-
). All experimentswere done in triplicates; error bars represent standard error of themean
5.
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contained a varying number of malignant cells with admixture of benign
mesothelial cells and inﬂammatory cells. All diagnoses were established
according to the guidelines of cytological diagnosis ofmalignant effusions
[41] and veriﬁed by histopathology, immunohistochemistry, ultrastruc-
tural or biomarker analyses. Thebenign effusions consistedof pleuritis ex-
udates, reactive mesothelial hyperplasia and/or displayed low biomarker
level for hyaluronan (HA). The percentage ofmalignant cellswas estimat-
ed considering cytomorphological and immunohistochemical parameters
independently by two expert pathologists (A. Hjerpe and K. Dobra).
Discrepant cases were resolved through discussion. The median age of
mesothelioma patientswas 67 (32–83) years, while for the benign or bio-
marker negative patients 72 (58–86) years.
The study was approved by the ethical review board of Stockholm,
Sweden (2009/1138-31/3), and the ethical review board of Eskisehir
University, Turkey. All patients provided informed consent.
All sampleswere centrifuged at 1700 g for 10min and acellular super-
natants were stored at−80 °C. SDC1 and SULF1 were measured using
ELISA kits, Human CD138 (syndecan-1) (Gen-Probe Diaclone, France,
cat. no. 950.640.192) and Human SULF1 (QAYEE-Bio, Beijing, China, cat.
no. QY-E02238), respectively. ELISAs were performed according to the
manufacturers' instructions. Effusions were diluted 1:3 for SDC1 analysis
and 1:5 for SULF1 measurements using dilution buffers as blanks. Patient
sampleswere analyzed in duplicate. Investigatorswere blinded to patient
diagnoses. Optical densities were determined using a spectrophotometer
(BioTek's PowerWave HT, Winooski, VT, USA) at 450 nm.
2.13. Survival analysis
Survival times were available for a sub-set of patients. To establish if
the level of SULF1 correlateswith the survival ofmesotheliomapatients,
survival analysis was performed with cut-off values based on the
highest and most signiﬁcant hazard ratio using the online web applica-
tion Cut-off Finder [42] as previously described [38]. With determined
cut-offs, the Kaplan–Meier survival analysis was applied. The log-rank
(Mantel–Cox) test compared survival curves and estimated hazard ra-
tios and p-values.
2.14. Cell cycle analyses
Cells were seeded in 12-well plates at a density of 105 cells/well.
After 24 h, the medium was removed and substituted with 500 μL of
freshmedium containing 2.5mMMgCl2. Tenmicroliters of recombinantFig. 2. SDC1 alters expression of different antibodies recognizing variously sulfated regions
ofHS chains. The expression of antibodieswas detectedusingmousemonoclonal anti-VSV
tag glycoprotein followed by Alexa 488-conjugated goat anti-mouse antibody and quanti-
ﬁed by FACS analysis. Results are expressed in fold change (FC) of HS epitopes in SDC1
over-expressing cells compared to control cells. Experiments were done in triplicates;
error bars represent standard error of the mean (SEM). Signiﬁcance was assessed by one
sample t-test. Asterisk indicates signiﬁcance at p ≤ 0.05.
Fig. 3. Exogenous SULF1 speciﬁcally reverts the effect of SDC1 over-expression on
RB4EA12 antibody. Cells were incubated 2 h in a serum free medium with or without
SULF1, stained with antibody RB4EA12 (a, b) or HS4E4 (c). Average of 3 experiments
(a) and representative FACS histogram plots (b, c) are shown. The expression of the
HSRB4EA12 epitope (a, b) in SDC1 over-expressing cells (gray line) is higher than control
cells (dashed line), and is reverted to the level of control cells in SDC1 over-expressing
cells supplementedwith exogenous SULF1 (black line). On theHS4E4 antibody (c), an epi-
tope not requiringO-sulfation, a slight elevation is seen due to SDC1over-expression com-
pared to control cells (light plots), however, addition of SULF1 does not revert this effect
(shaded plots).
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trypsinized, centrifuged, ﬁxed in 1 mL of 70% cold ethanol in test
tubes, and incubated at 4 °C overnight. Cells werewashed in PBS and re-
suspended in 500 μL staining solution containing 50 μg/mL propidium
iodide (Sigma-Aldrich, MO, USA) and 100 μg/mL RNAse A (Sigma-Al-
drich, MO, USA). The cells were incubated for 30 min at 37 °C. The cell
cycle distribution was acquired for 10,000 cells for each sample using
a FACSCalibur cytometer (Becton Dickinson, CA, USA) with ModFit LT
software (Verity Software House, ME, USA).
2.15. Statistical analysis
Statistical analyses were performed using GraphPad Prism version
6.01 for Windows (GraphPad Software, San Diego California USA,
www.graphpad.com). Normal distribution was tested by D'Agostino &
Pearson's omnibus normality test. Signiﬁcance was analyzed using the
two-tailed Student's t-test, two-way ANOVA, or Mann–Whitney non-
parametric test depending on the comparisons and distribution pattern.
Signiﬁcancewas considered at p b 0.05. The correlation between soluble
SDC1 and SULF1 in paired effusions was analyzed using a two-tailed
Pearson correlation.
3. Results
3.1. Syndecan-1 over-expression alters the expression of HS biosynthetic/
modifying enzymes
To investigate the impact of SDC1 on HS biosynthetic andmodifying
machinery, we studied the RNA and protein levels of fundamentalFig. 4. Composition analysis of HS chains from cells over-expressing SDC1 revealed clear change
structural analysis (c) by RPIP-HPLC of HS puriﬁed from medium (M0, white bars) and cell lys
lysates (CS1, dashed bars) of SDC1-transfected STAV-AB cells. Error bars represent SEM of tripcomponents involved in this process. The RNA levels of HS biosynthetic
and modifying enzymes (EXT1, NDST1, HS2ST1, HS6ST1, SULF1) and
the sulfate donor synthase PAPSS1 were altered after SDC1 over-
expression (Fig. 1a). The most dramatically altered enzyme was
SULF1, which was down-regulated N50-fold at the RNA level, whereas
the synthesized protein was down-regulated 1.8-fold compared to the
control (Fig. 1b). The expression ofHS2ST1proteinwas slightly elevated
in the SDC1-over-expressing cells. In contrast, NDST1 and HS6ST1 were
down-regulated at the RNA level, thoughwe did not observe any signif-
icant changes in protein expression (Fig. 1b).
3.2. Syndecan-1 over-expression alters the sulfation pattern of HS chains
To check how changes in HS synthetizing and modifying enzymes
affect the sulfation pattern of HS chains, we used antibodies against var-
ious sulfated saccharide motifs and performed further precise analyses
of the disaccharide content.
In agreement with SULF1 down-regulation and the altered expres-
sion of the enzymes involved in HS synthesis, the use of phage-
displayed antibodies indicated modiﬁcations in the HS structure. Bind-
ing of the antibody RB4EA12, which preferentially recognizes N- and
6-O-sulfated saccharide motifs, was signiﬁcantly elevated in cells over-
expressing SDC1, suggesting higher contents of 6-O- and N-sulfation
(Fig. 2). Moreover, addition of SULF1 to the culture medium reverted
this effect of the RB4EA12 antibody (Fig. 3).
The chromatographical analysis of HS from control cells and cells
over-expressing SDC1 also revealed clear changes in polysaccharide ex-
pression and structure. First, SDC1 over-expression resulted in lower
amounts of HS, with a 2.5 to 2.7-fold reduction in both medium ands in polysaccharide expression and structure compared to control. Quantiﬁcation (a, b) and
ates (C0, gray bars) of control STAV-AB cells, and frommedium (MS1, black bars) and cell
licate analysis.
Fig. 5. Cells over-expressing SDC1 bindmore exogenously added SULF1. Cells were seeded
on slides, incubated with SNAP-tagged SULF1 for 30 min and ﬂuorescently tagged with
Alexa 488 SNAP substrate. Cell's nuclei were counterstained with Hoechst dye and ana-
lyzedwith a laser confocalmicroscope. (a) Bound SULF-1was quantiﬁed based on twodif-
ferent experiments,ﬁve random images each containing at least 10 cells/image. Total pixel
intensity/cell was evaluated in the green channel and analyzedwith ImageJ software. Sig-
niﬁcance was assessed by Mann–Whitney t-test. (b) Representative confocal micrograph
showing cell-surface bound SULF1 (green) and cell nuclei (blue).
Table 4
Structural analysis of HS composition from control and SDC1 transfected STAV-AB cells:
sulfation content (number of sulfates per 100 disaccharides).
Control SDC1 over-expressing
Medium Cells Medium Cells
N-Sulfation 49.7 50.8 58.3 61.6
2-O-sulfation 30.3 30.8 31.6 36.7
6-O-sulfation 23.6 25.3 32.1 35.8
Total sulfation 103.7 106.8 122 134.1
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was higher (~20%), with notable increases in N-sulfation and 6-O-
sulfation (Table 4). A detailed analysis of disaccharide content (Fig. 4c)
showed that the main changes occurred for 6-O-sulfated disaccharides,
which is consistent with the reduced expression of SULF1 in these cells.
The disaccharide [ΔUA(2S)–GlcNS(6S)] is the major substrate of SULF
and was the most affected, with an increase of ~2.5-fold accompanied
by a decrease in [ΔUA(2S)–GlcNS] (theproduct of the enzyme reaction),
though not to the same extent. In contrast, the other 6-O-sulfated disac-
charides [ΔUA–GlcNS(6S)] and [ΔUA–GlcAc(6S)], which are poor sub-
strates for the enzyme [36], were decreased, suggesting the existence
of cellular compensatory mechanisms to sustain an even amount of 6-
O-sulfation. Notably, very little difference was observed between cell
surface and extracellular HS in the culture medium. This ﬁnding is in
agreement with the principle of a universal biosynthetic machinery
being responsible for HS assembly on all proteoglycans, as the extracel-
lular environment contains not only shed syndecans, but also other
HSPGs. The identity of the disaccharides was also veriﬁed by HPCE anal-
ysis. Due to a low amount of sample, just a few types of sulfated disac-
charides were detected by this method, but the results were similar to
those of the previous method: a signiﬁcant increase in mono N-
sulfated disaccharides and decrease in [ΔUA(2S)–GlcNS] and [ΔUA–
GlcNS(6S)] disaccharides in cells over-expressing SDC1 (data not
shown).
3.3. Syndecan-1 over-expression enhances binding of exogenous sulfatase-
1 to the cells
In order to examine the binding capacity of HS chains with altered
sulfation pattern in SDC1 over-expressing cells, exogenous SNAP-
tagged SULF1 was used to probe cell surface HS for SULF binding se-
quences. Cells over-expressing SDC1bound signiﬁcantlymore of the ex-
ogenous enzyme. This result indicates the presence of larger amounts of
intact 6-O-sulfated HS motifs, which is consistent with the reduced ex-
pression of endogenous SULF1 (Fig. 5). Notably, the cells grown under
serum-free conditions at 37 °C internalized some of the added SULF1
within a few hours (data not shown).
3.4. Syndecan-1 modulates multiple intracellular signaling pathways
To study whether changes in HS chains lead to alterations in down-
stream signaling we measured the phosphorylation status of different
kinases and receptors after growth factor stimulation. Among the 41
studied mitogen-activated protein kinase (MAPK)-related components,
18 phosphorylatedmembers of this family, mainly transcription factors,
were detected in all three experiments.
Using two independent methods, the activity of EGFR was found
consistently higher in cells over-expressing SDC1 compared to controls,
although the variability between experiments was too large to give sta-
tistical signiﬁcance. Phospho-kinase array showed 1.8 ± 0.3 fold higher
EGFR activity in SDC1 over-expressing cells (mean ± SEM), (Fig. 6),
while the difference was 1.6 ± 0.5 fold using the phospho-RTK array.
The other RTKs were not inﬂuenced.
Downstream of the signaling pathways, ERK1/2 phosphorylation
was slightly increased (1.2 ± 0.16), whereas the phosphorylation of
protein kinases WNK1 and Akt 1/2/3 were decreased in cells over-
expressing SDC1 compared to control cells (0.6 ± 0.09, and 0.3 ± 0.08
fold change, respectively) (Fig. 6). Flow cytometry analysis conﬁrmed
the elevated levels of both total and phospho-ERK1/2 (1.74-fold and
6.1-fold, respectively), in cells over-expressing SDC1 compared to con-
trol cells (Fig. 7a–b). Theseﬁndingswere veriﬁed by immunocytochem-
istry (Fig. 7c). Similarly, inhibition of Akt expression and activity was
also conﬁrmed by FACS analysis; we measured 0.48 ± 0.025 and
0.5 ± 0.0018-fold changes for total and phospho Akt, respectively
(Fig. 8).Downstream of phospho-kinases, among the ERK1/2 (MAPK) regu-
lated transcription factors, the activity of c-Jun was inhibited by SDC1
over-expression (mean fold change ± SEM; 0.74 ± 0.07, Fig. 9). Fur-
thermore, in cells over-expressing SDC1, the expression of the ETS-1
transcription factor increased by 1.62 ± 0.15 fold, but its activity was
not affected (Fig. 10).
3.5. Both syndecan-1 over-expression and exogenous sulfatase-1 affect the
cell cycle
To check if cell cycle is affected by SDC1 and SULF1, we investigated
the cell cycle distribution in cells over-expressing SDC1 and mock con-
trols in the absence and presence of SULF1. Cells that overexpressed
SDC1 showed a signiﬁcantly larger proportion of cells in G0/G1 phase
compared to the mock-transfected ones (66.5 ± 2.3 vs. 61.3 ± 0.7, re-
spectively), with correspondingly less cells in S- and G2/M phases
(26.3 ± 2.9 vs. 30.7 ± 0.7 and 7.2 ± 0.6 vs. 8 ± 0.0, respectively). Sur-
prisingly the exposure to exogenously added SULF1 decreased the pro-
portion of S- and G2/M cells, both in the SDC1 overexpressing cells (to
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26.9± 0.6 and 7.9± 0.1), while the proportion of G0/G1 cells increased
correspondingly (to 72.1 ± 1.1 and 65.1 ± 0.7) (Fig. 11).
3.6. Sulfatase-1 expression is low in malignant pleural effusions
In order to test the applicability of our ﬁndings in clinical settings
and the potential role of SULF1 as a biomarker in malignant mesotheli-
oma, we measured its levels in pleural effusions. SULF1 levels were sig-
niﬁcantly lower in malignant pleural effusions (mean ± SEM; 49.3 ±
3.3; n = 56) compared to benign conditions (118.5 ± 8.7; n = 10;Fig. 6. Phospho-kinase proﬁle of SDC1 over-expressing cell lysates compared to the control. Ce
weremixedwith a cocktail of detection antibodies and added onmembranes coatedwith prima
resentative images of human phospho-kinase arrays of 300 μg cell lysate from SDC1 over-expres
three experiments. Duplicates represent following proteins in numerical order: P38a (1); ERK1
tenin (9); STAT2 (10); STAT5a (11); STAT6 (12); STAT5b (13); Chk-2 (14); C-Jun (15); STAT3 (
duplicates. Fold changeswere calculatedbased on the average optical density values of each ana
of control cells. Asterisk represents a signiﬁcant difference (p-value b 0.05) and # indicates p-v
resent standard error of the mean (SEM). Analyses were performed and graphs were created up b 0.0001, Fig. 12a). Within the malignant group, SULF1 was signiﬁ-
cantly lower in pleural effusions from mesothelioma patients (39.9 ±
2.8; n = 39) compared to effusions from adenocarcinoma patients
(69.3± 5.3; n= 17; p b 0.0001, Fig. 12b). By simultaneouslymeasuring
the level of soluble SULF1 and SDC1 in pleural effusions from mesothe-
lioma patients, we found a fair, though not signiﬁcant, inverse correla-
tion between SULF1 and SDC1 expression (r =−0.43; p = 0.13; n =
13, Fig. 12c).
Pleural effusions contained in average 40% tumor cells (ranging from
10 to 80%). Soluble SDC1 strongly correlated with the tumor burden
represented by the proportion of tumor cells (r = 0.8; p = 0.006)lls were stimulated with VEGF+ PDGF, and equal amounts of total proteins in cell lysates
ry antibodies. Chemiluminescencewas detected for each spotwith a CCD camera. (a) Rep-
sing cells (top) and controls (bottom). Eighteen proteins in duplicateswere detected in all
/2 (2); JNK1/2/3 (3); GSK-3a/b (4); EGFR (5); MSK1/2 (6); Akt1/2/3 (7); CREB (8); B-ca-
16);WNK1 (17); and HSP60 (18). (b) Three independent experiments were performed in
lyte obtained fromSDC1over-expressing cells divided by the average optical density values
alue = 0.06. p-Values are from Student's t-tests. Lines represent mean and error bars rep-
sing the GraphPad Prism software.
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found between SULF1 levels and tumor burden.
SULF1 levels did not correlate to the survival of malignant mesothe-
lioma patients (r = 0.12; p = 0.5, data not shown). Using the cut-off
value of 36.57 ng/mL based on the highest and most signiﬁcant hazard
ratio, median survival time of mesothelioma patients with SULF1 level
higher than 36.57 ng/mL was 10 months, while in those with lower
SULF1 levels it was slightly lower, 6 months. However, this difference
was not statistically signiﬁcant (hazard ratio 0.76; 95% CI = 0.37 to
1.6; p = 0.47; Supplementary Fig. 1).
4. Discussion
The cancer-related signiﬁcance of SDC1 has been established in a
wide range of tumors, including mesothelioma, breast, colorectal,Fig. 7. The level and the activity of ERK1/2 are elevated due to SDC1 over-expression. Cells ove
phospho ERK1/2. The expression and activity of ERKs were quantiﬁed by ﬂuorescence activate
Average geometrical mean of the ﬂuorescent intensities of three experiments, based on FACS an
of the difference between total and phospho-ERKwas assessed by Student's t-test. Asterisk rep
where dotted lines represent intensity of control cells, whereas black line represents SDC1 ove
ERK1/2 or pERK1/2 detected by Alexa 488, and blue represents nuclei stained with Hoechst dygastric, pancreatic, prostate, lung, endometrial, and ovarian cancers, as
well as squamous cell carcinoma of the head and neck [26,43]. However,
the net effect exerted by SDC1 is largely tissue-speciﬁc and depends on
the sub-cellular localization of proteoglycans, the ratio of shed and cell-
bound SDC1, tumor–matrix interactions, and the concentrations of
available growth factors and mitogens in the tumor microenvironment.
Generally, mesothelioma cells express low levels of SDC1 and cells with
higher levels of membrane-bound SDC1 undergo epithelioid differenti-
ation, associated with a better prognosis than sarcomatoid mesothelio-
mawith little or no expression of this proteoglycan [26]. We previously
demonstrated that SDC1 inhibits tumor cell growth, proliferation, and
migration in MM cells [29,44]. Furthermore, our recent study indicates
that soluble SDC1 can serve as a diagnostic and prognostic marker for
pleural malignancies, such as mesothelioma andmetastatic adenocarci-
noma [38].r-expressing SDC1 and control cells were stimulated with FGF2, stained with ERK1/2 and
d cell sorting (FACS) (a, b) and immunostaining followed by confocal microscopy (c). (a)
alysis. Results are represented as average fold changes+/− SD. The statistical signiﬁcance
resents a signiﬁcant difference (p-value b 0.05). (b) A representative FACS histogram plot,
r-expressing cells. (c) Immunostaining followed by confocal microscopy, green indicating
e.
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of HS-binding proteins (HSBPs), known as theHS interactome, and is in-
volved in various cellular processes [45,46]. All these processes begin
with physical docking of the biological effectors to saccharide motifs
within the HS chains. Therefore, the modiﬁcation of such motifs has a
crucial impact on the biological functions of HSPGs by modulating the
binding capacity and/or speciﬁcity of HSBPs and altering downstream
signaling pathways [47,48], leading to potential inhibitory or stimulato-
ry effects on tumor growth. However, the impact of SDC1 expression on
the structural and functional properties of HS in mesothelioma, and its
implications on intracellular signaling pathways, have never been
investigated.
In this context, the present study demonstrates for the ﬁrst time that
SDC1 over-expression affects the composition of HS chains through alter-
ations in both biosynthetic and post-synthetic modiﬁcation processes.
HS biosynthesis and turnover are strictly regulated processes involv-
ing many enzymes interrelated to each other [49,50]. In the course of
their synthesis in Golgi, HS chains are elongated by exostosins (EXT1-2).
The N-deacetylase–N-sulfotransferases (NDST 1–4) continue the biosyn-
thetic process by replacing the acetyl group of GlcNAc with a sulfate
group, introducing HSN-sulfation. In subsequent steps, the corresponding
O-sulfotransferases (HS2ST1, HS6ST1–3, HS3ST1–7) preferentially add
their sulfate groups to an alreadyN-sulfatedmotif [51,52]. Finally, mature
HS chains at the cell surface can be modiﬁed by extracellular HS 6-O
endosulfatases (SULF1 and 2), which can selectively remove 6-O sulfate
groups from the polysaccharide [53]. Therefore, the edition of a precise
HS sulfation pattern relies on a tight balance between these biosynthetic
and post-synthetic enzymatic processes. Previous studies have suggested
a dynamic interplay between all of these enzymes that may add further
complexity to the system. Over-expression of EXT1 or EXT2 inhibits or
enhances NDST1 expression, respectively, with opposite consequences
on HS sulfation [54]; NDST1-deﬁcient mice exhibit general HS under-
sulfation, suggesting that NDST1 plays a dominant role in the regulation
of HS synthesis [32,55]. Moreover, over-expression or knock-down of
SULFs has been shown to lead to alterations in the 6-O-sulfation pattern,
and 2-O andN-sulfations are also signiﬁcantly affected [56–58]. Taken to-
gether, the results indicate that postulating direct cause–effect relation-
ships between variations in biosynthetic enzyme expression and HS
structure is questionable.
Here, we characterized HS from intact and SDC1-over-expressingme-
sothelioma cells using three complementary approaches: transcriptionalFig. 8. The level and the activity of Akt are inhibited by SDC1 over-expression. Cells over-expres
expression and activity of Akt were quantiﬁed by ﬂuorescence activated cell sorting (FACS). (a
FACS analysis. Results are represented as average fold changes +/− SEM. The one sample t-test
difference (p-value b 0.05). (b) A representative FACS histogram plot, where dotted lines repreanalysis of HS biosynthesis enzymes, mapping of saccharide epitopes
using phage-display anti-HS antibodies, and biochemical determination
of HS composition by disaccharide analysis. These strategies revealed
clear changes in HS structure upon SDC1 over-expression that can con-
tribute to altered signaling. We show that the expression of enzymes
fromnearly every step of HS biosynthesis and post-synthesis are delicate-
ly affected by SDC1. One possible mechanism of these effects could be a
negative feed-back in the cells expressingmore SDC1, resulting in slower
biosynthetic processes, as suggested by the ﬁnding that both EXT1 and
NDST1 are transcriptionally down-regulated. Disaccharide analysis
showed that HS chains were less abundant in cells over-expressing
SDC1, which may be due in part to decreased synthetic capacity of the
HS biosynthetic machinery in cells over-expressing the SDC1 protein
core, and in part due to the decreased amount of EXT1 and NDST1 en-
zymes leading to the assembly of shorter HS chains. Such a phenomenon
has been observed in xyloside-treated cells [31]. In addition, SDC1 over-
expression could result in the down-regulation of other HSPGs [27,29].
Transcriptional analysis showed that the expression of both HS6ST1
and SULF1 decreased upon SDC1 over-expression. This may be another
indication of a slower biosynthesis and turnover of HS in these cells, par-
ticularly of 6-O-sulfated moieties. Our results indicate that modiﬁcations
of 6-O-sulfation on HS chains were qualitative rather than quantitative.
The overall 6-O-sulfate content remained unchanged, but disaccharide
analysis revealed a drastic increase in [ΔUA(2S)–GlcNS(6S)] and decrease
in [ΔUA–GlcNS(6S)] and [ΔUA–GlcNAc(6S)]. Enhanced [ΔUA(2S)–
GlcNS(6S)] is a direct consequence of SULF1 down-regulation, as this spe-
ciﬁc disaccharide is a preferential substrate of the enzyme. However, this
increase was only partially compensated by a decrease in [ΔUA(2S)–
GlcNS], the product of SULF1 desulfation. This ﬁnding indicates that the
observed modiﬁcations cannot be attributed exclusively to a depletion
of SULF1 enzymatic activity, but also involves ﬁne tuning of the HS struc-
ture through the biosynthesis machinery. Recently, a study on colorectal
cancer cells over-expressing SULFs reported an increase in GlcNAc(6S)-
containing disaccharides as a cellular response that compensates for the
enzymatic driven decrease in [ΔUA(2S)–GlcNS(6S)] [59]. Our data
support such complementary behavior, here in the context of SULF1
down-regulation by SDC1. The results obtained with anti-HS phage-
display antibodies are in full agreementwith these ﬁndings; an enhanced
signal was observed for RB4EA12 antibody, which recognizes 6-O-
sulfated and N-sulfated epitopes, respectively, furthermore a relative in-
crease was noticed for NS4F5, which has speciﬁcity towards [ΔUA(2S)–sing SDC1 and control cells were stimulated, stainedwith total- and phospho Akt1/2/3, the
) Average geometrical mean of the ﬂuorescent intensities of three experiments, based on
with a theoretical mean of 1 was applied for signiﬁcance. Asterisk represents a signiﬁcant
sent intensity of control cells, whereas black line represents SDC1 over-expressing cells.
Fig. 11. Cell cycle distribution is altered after exogenous SULF1 addition to syndecan-1
over-expressing cells and controls. Cell cycle analyses were performed by PI staining,
24 h after SULF1 addition using ﬂow cytometry. Columns represent mean percentage of
cells in each phase of the cell cycle ± SD (n = 3). p-values are calculated by two-way
ANOVA test. Asterisks indicate statistically signiﬁcant differences (*p b 0.05, **p b 0.01,
***p b 0.001, ****p b 0.0001). SD = standard deviation.
Fig. 9.MAPK regulated transcription factor activity is altered in SDC1 over-expressing cells
compared to the control. Cells' nuclear extracts were added to the 96well-plate with coat-
ed oligonucleotides. The amount of bound transcription factor was quantiﬁed using anti-
bodies speciﬁc for each activated transcription factor form and optical densities were
determined. Four independent experiments were performed in triplicates. Fold changes
were calculated based on the average optical density values of SDC1 over-expressing
cells and were obtained from each experiment for each transcription factor, divided by
the average optical density values of control cells. Asterisk represents a signiﬁcant differ-
ence (p-value ≤ 0.05). p-Values are calculated by two tailed Student's t-tests. Lines repre-
sent mean and error bars represent standard error of the mean (SEM).
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activity [36].
We also found that the HS chains of cells over-expressing SDC1were
more N-sulfated and 2-O-sulfated. The latter result was expected, as we
observed an increase in HS2ST expression at both the transcriptional
and protein levels. However, no such correlation could be made be-
tween enhanced N-sulfation of HS and decreased expression of
NDST1. Explanations for this may be that, in contrast to HS2ST, NDSTs
display three other isoforms that may contribute to compensatory
mechanisms. In addition, we did not observe any signiﬁcant down-
regulation of NDST1 at the protein level. Finally, increased N-sulfation
could also be the result of the down-regulation of EXT1, which has
been reported to inhibit NDST1 activity [54].
To conﬁrm our hypothesis that many of the observed changes in HS
chain composition in cells over-expressing SDC1 is related to the sub-
stantial down-regulation of SULF1 expression, we showed that the
binding of exogenous SULF1 to HS chains is more extensive in cells
over-expressing SDC1 and that treatment with SULF1 can revert the
binding of 6-O-sulfate-dependent RB4EA12 antibody. As mentionedFig. 10. SDC1 over-expression increases the level of ETS1 but its activity is not inﬂuenced. Cells
ETS1 and phosphoT38 ETS1. The expression and phosphorylation of ETS1 were quantiﬁed by ﬂ
based on the geometrical mean of the intensities measured by FACS. Results are average fold ch
icance. Asterisk represents a signiﬁcant difference (p-value b 0.05). (b) A representative FACSabove, SULF1 post-synthetically removes the 6-O-sulfate groups of HS
chains and plays conﬂicting roles as an oncogene or tumor suppressor
in various cancers. The 6-O-sulfation level has been reported to change
throughout the different stages ofmalignancy, resulting in an alteredHS
structure and function [18–20]. Growth factor binding and presentation
to cognate receptors can be differentially regulated according to the HS
sulfation pattern, as exempliﬁed for FGF-2; binding of HS to the growth
factor is 2-O-sulfation-dependent, whereas binding to FGF2-receptor is
6-O-sulfation-dependent.
Consequently, modiﬁcations of the HS 6-O-sulfation status by SULFs
are critical in tumor cell survival, proliferation, andmetastasis. Our ﬁnd-
ing that SDC1 over-expression directly inhibits SULF1 and leads to in-
creased HS 6-O-sulfation suggests functional consequences regarding
the binding of growth factors and the regulation of intracellular signal-
ingpathways, as previously observed for VEGFR [60], amphiregulin [61],
and FGFR [62]. In our study, this is illustrated by a subtle enhancement
of EGFR activity in cells over-expressing SDC1 and concomitant activa-
tion of the downstream ERK1/2 pathway. However, the ultimate effect
of SDC1 over-expression is the inhibition of proliferation [29] retaining
the cells in G0/G1, thus we hypothesize that other inhibitory mecha-
nisms may be involved that are triggered by SDC1, but are independent
of HS chain modiﬁcations. This hypothesis is supported by two main
ﬁndings: ﬁrst, the G1 arrest observed in SDC1 over-expressing cells
could not be rescued by SULF1 addition. Second, despite the ERK activa-
tion, downstream ERK-related transcription factors are inhibited. We
analyzed the expression and activity of ETS-1, as we previously found
that it is the only transcription factor affected at the RNA level by bothover-expressing SDC1 and control cells were stimulated for 5 minwith FGF2, stained with
uorescence activated cell sorting (FACS). (a) Represents the average of three experiments,
anges +/− SD. The one sample t-test with a theoretical mean of 1 was applied for signif-
plot; gray line represents control cells, and black line SDC1 over-expressing cells.
Fig. 12. Soluble SULF1 is present in lower levels inmalignant tumors and negatively correlateswith soluble SDC1 in pleural malignancies. (a) Soluble SULF1 levelswere signiﬁcantly lower
in pleural effusions frommalignant tumors compared to benign effusions. (b)Within themalignant tumors, pleural effusions frommesothelioma patients had signiﬁcantly lower levels of
SULF1 compared to adenocarcinoma patients. p-values are calculated fromKruskal–Wallis tests. Lines representmean and error bars represent standard error of themean (SEM). (c) Pear-
son correlation analysis was used to assess the relationship between soluble SDC1 and SULF1 in paired sample effusions from 13 mesothelioma patients.
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gene which is activated by ERK1 at threonine-38 residue. We found
that, though the level of ETS-1 is elevated in cells over-expressing SDC1,
its phosphorylation at threonine-38 was not inﬂuenced. Considering the
elevated ETS1 expression and unchanged phosphorylation, we conclude
that ETS-1 activation was inhibited via a signaling pathway independentFig. 13.High levels of soluble SDC1 inmalignant pleural effusions correlatewith the percent-
age of tumor cells. Higher soluble SDC1 levels exceeding a cut-off level of 235 ng/mLpositive-
ly correlate with tumor burden represented by the percentage of tumor cells in malignant
pleural effusions. Tumor cell percentage was estimated using cytomorphological and immu-
nohistochemical parameters, the level of soluble syndecan-1wasmeasured by ELISA. Cut-off
values for “high” (n = 9) and “low” (n = 13) SDC1 expression were the same with the one
identiﬁed in our previous study [38] using the online web application Cut-off Finder [42]. R
and p-values were calculated using Pearson correlation.of ERK1/2. c-Jun activity is also inhibited by SDC1 over-expression. Previ-
ously it was shown that c-Jun is activated by both the ERK1/2 and JNK
pathways [63]. As a member of the activator protein-1 (AP-1) family, c-
Jun activity is also necessary for the expression of cyclin D1, which elicits
G1/S transition and cell cycle progression [64]. Our previousﬁndings from
a transcriptomic array also showed low cyclin D1 levels after SDC1 over-
expression [27]. The low c-Jun activity could partly explain the absence of
downstream effects upon ERK1/2 activation and the G1/S arrest of meso-
thelioma cells over-expressing SDC1.
Additionally, several key factors fromother signaling pathwayswere
inhibited downstreamof RTKs in the signaling cascade.WNK1, a regula-
tor kinase ofMAPK in EGFR signaling,wasmoderately inhibited by SDC1
over-expression. WNK kinases affect multiple signaling pathways in-
volved in proliferation and are known to be apoptosis inhibitors [65].
WNK1has been reported to be fundamental for EGF signaling via activa-
tion of ERK5 [66]. Suppressed ERK5 activation and hampered cell
growth have been reported in vivo after WNK1 down-regulation [67].
The low activity of WNK1 caused by SDC1 can be another mechanism
by which the effects of ERK1/2 activation are attenuated. Furthermore,
our data show that SDC1 is a potent inhibitor of Akt1/2/3 activity. This
is particularly interesting in light of the studies showing that the PI3K/
AKT pathway plays a critical role inMM, inwhich Akt is generally highly
activated [68,69] and depends on RTKs, whereas MAPK activation was
shown to be independent of receptor activation status [70]. Moreover,
Akt1/2/3 is an important factor in the G1/S transition checkpoint. Inhi-
bition of PI3K activity in different MM cell lines led to signiﬁcant G1
cell cycle arrest and the suppression of cell proliferation associated
with down-regulation of cyclin D1 [71]. Our results support the idea
2066 G. Heidari-Hamedani et al. / Cellular Signalling 27 (2015) 2054–2067that the G1 arrest in cells over-expressing SDC1 can bemediated by Akt
inhibition. Thereby we provide new evidence of the importance of Akt
signaling in MM cell proliferation and cell cycle.
In light of the effects of the signaling events caused by SDC1 over-
expression, the inhibition of different signaling pathways at multiple
levels may counteract the initial ERK activation. This is also manifested
by a general inhibition of the MAPK/ERK pathway downstream of
ERK: ETS1, c-Jun, and ultimately cell cycle and proliferation.
The level of SULF1 is lower in malignant pleural effusions than be-
nign effusions. This ﬁnding is in line with several cancers that have
been reported to express low levels of SULF1, including ovarian cancer,
hepatocellular carcinoma, kidney, gastric, and bladder cancers [10], im-
plying a tumor suppressor nature of SULF1 [72,73]. However, another
study has reported that SULF1 is elevated at the transcriptomic level
in mesothelioma, which could partly be involved in chemo-resistance
[74]. The low level of SULF1 in pleuralmalignanciesmay result in higher
HS 6-O-sulfation, which may in turn result in increased growth factor
binding and growth promotion. Within the malignant group, mesothe-
lioma samples had a lower level of SULF1 than adenocarcinoma, which
may reﬂect the highly malignant behavior of this cancer. This observa-
tion is in agreement with our in vitro ﬁndings of elevated ERK1/2 levels
and activity and enhanced growth factor binding capacity. Yet we could
not show a signiﬁcant correlation between the level of SULF1 and pa-
tient survival; patients with higher SULF1 level had slightly longer me-
dian survival time, though this association was not signiﬁcant. Testing
the role of SULF1 as a prognostic marker needs a larger clinical material.
Our results, however, indicate that SULF1 potentially can be included in
a panel of diagnostic markers to distinguish adenocarcinomas from
mesotheliomas.
Comparisons in a cohort of pleural effusions frommesothelioma pa-
tients indicated that soluble SDC1 was inversely correlated to SULF1.
We have previously reported that pleural effusions frommesothelioma
patients contain higher levels of shed SDC1 compared to benign pleural
effusions and these high levels of shed SDC1 correlate to shorter survival
[38], while high levels ofmembrane-bound SDC1 has been associated to
better prognosis [26]. The localization of SDC1 is crucial: In malignant
mesothelioma SDC1 is expressed mainly at the membrane of the
tumor cells with epitheloid phenotype and in the epithelial component
of biphasic mesotheliomas which are associated with a less aggressive
biological behavior and longer survival. Noteworthy, shed SDC1 may
act in opposite way asmembrane HSPGs by interferingwith the growth
factor gradients in the environment of tumor cell [13].Whether lowered
level of SULF1 is speciﬁcally due to shed or membrane-bound SDC1 in
mesothelioma patients remains to be elucidated, nevertheless these
ﬁndings support our in vitro observations that SDC1 inhibits SULF1 in
malignant mesothelioma cells. One disclosed mechanism of SULF1
down-regulation in different tumor types is silencing by hyper-
methylation of its promoter [75]. Here, we provide evidence of a novel
inhibitory mechanism controlled by SDC1 expression. Taken together
we show here that cell surface SDC1 inhibits SULF1 expression in vitro
and causes a cell cycle arrest in G1 phase. In clinical material shed
SDC1 inversely correlates with SULF1, adding further evidence to the
notion that soluble- and cell-surface SDC1 may counteract each other,
inﬂuencing tumor cell behavior.
5. Conclusions
This study supports a crucial role of SDC1 inmodifying theﬁne struc-
ture and sulfation pattern of proteoglycans, mainly through down-
regulation of SULF1, affecting downstream signaling. The results pro-
vide new evidence that enhanced proteoglycan core protein expression
also ﬁnely modulates HS expression and structure by interfering with
HS biosynthetic/modifying enzymes. By performing complex HS bio-
chemical characterization using three different approaches, we provide
further evidence of a complex interplay between HS biosynthesis and
post-synthetic modiﬁcations. Furthermore, this work contributes toelucidating the intricate role of SDC1 in signaling by revealing that
SDC1 acts through the PI3K and MAPK signaling pathways in MM
cells, ultimately leading to cell cycle disruption by G1 arrest. Our results
suggest a potential role as a diagnosticmarker of SULF1 in pleuralmalig-
nancies and provide further insight into the complex role of SDC1 and
SULF1 in cancer.
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